2.3900
-0.1100
(-4.40%)
As of 12:16:45 PM EDT. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 3 | 4 | 3 |
| Avg. Estimate | -0.18 | -0.26 | -0.88 | -1.08 |
| Low Estimate | -0.23 | -0.3 | -0.92 | -1.36 |
| High Estimate | -0.14 | -0.23 | -0.84 | -0.86 |
| Year Ago EPS | -0.25 | -0.29 | -1.14 | -0.88 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 4 | 5 | 5 |
| Avg. Estimate | -- | -- | 4.8k | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | 8k | -- |
| Year Ago Sales | -- | 8k | 170k | 4.8k |
| Sales Growth (year/est) | 0.00% | -100.00% | -97.18% | -100.00% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.18 | -0.21 | -0.21 | -0.19 |
| EPS Actual | -0.25 | -0.29 | -0.22 | -0.19 |
| Difference | -0.07 | -0.08 | -0.01 | 0 |
| Surprise % | -38.89% | -40.32% | -6.02% | 0.00% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.18 | -0.26 | -0.88 | -1.08 |
| 7 Days Ago | -0.19 | -0.2 | -0.89 | -1.01 |
| 30 Days Ago | -0.19 | -0.22 | -0.89 | -1.18 |
| 60 Days Ago | -0.19 | -0.22 | -0.88 | -1.18 |
| 90 Days Ago | -0.19 | -0.23 | -0.88 | -1.22 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 1 | 1 |
| Up Last 30 Days | 1 | 1 | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | 1 |
| Down Last 30 Days | -- | -- | 2 | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| GNLX | 27.00% | 10.34% | 23.37% | -23.81% |
| S&P 500 | 6.68% | 6.74% | 9.91% | 14.34% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/31/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/25/2025 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 11/15/2024 |
| Initiated | Guggenheim: Buy | 10/29/2024 |
| Initiated | Roth MKM: Buy | 8/27/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/15/2024 |
Related Tickers
ARTV Artiva Biotherapeutics, Inc.
2.4000
-5.51%
RAPP Rapport Therapeutics, Inc.
8.20
-3.81%
TYRA Tyra Biosciences, Inc.
7.64
-7.95%
GDTC CytoMed Therapeutics Limited
2.2840
-7.90%
TRDA Entrada Therapeutics, Inc.
7.71
-3.87%
FBLG FibroBiologics, Inc.
0.8845
+1.09%
DSGN Design Therapeutics, Inc.
3.4000
-3.41%
ZURA Zura Bio Limited
1.0099
-6.92%
TSBX Turnstone Biologics Corp.
0.3651
-3.16%
ELTX Elicio Therapeutics, Inc.
5.84
+6.18%